Brief: Aslan Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of Eblasakimab
22/04/2024 13:52
April 22 (Reuters) - Aslan Pharmaceuticals Ltd
7A90y.BE :
* ASLAN PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS
FROM
PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC
DERMATITIS PATIENTS
* ASLAN PHARMACEUTICALS LTD: PRIMARY ENDPOINT OF STUDY WAS
STATISTICALLY SIGNIFICANT WHEN COMPARED TO PLACEBO
* ASLAN PHARMACEUTICALS LTD: TREATMENT WAS WELL-TOLERATED
AND NO
NEW SAFETY SIGNALS WERE IDENTIFIED
Source text for Eikon: ID:n0000950170-24-046201
Further company coverage: 7A90y.BE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aslan Pharmaceuticals
See all newsBrief: Aslan Pharmaceuticals Announces Plan To Implement ADS Ratio Change
Brief: Aslan Pharmaceuticals Ltd Files For Shelf Of Up To 61.9 Million Ordinary Shares By Selling Stockholder - SEC Filing
Brief: Aslan Pharmaceuticals Announces Expansion Of Its Collaboration With Zenyaku
Brief: Aslan Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of Eblasakimab
Brief: ASLAN Pharmaceuticals To Sell ADSs Having An Aggregate Offering Price Of Up To $12 Mln